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Introduction: Type 2 diabetes (DM2) is associated with greater risk for cardiovascular disease (CVD), which
may, at least partially, be explained by prothrombotic alterations. We therefore investigated; ﬁrst, the extent
to which individuals with impaired glucose metabolism (IGM) and/or DM2 had greater levels of thrombin
generation than those with normal glucose metabolism (NGM); and second, whether any differences were
independent of other cardiovascular risk factors, such as smoking, hypertension, dyslipidaemia, (micro)
albuminuria, glycemic control and (central) adiposity, and/or were potentially ‘mediated’ by low-grade
inﬂammation (high-sensitivity C-reactive protein (hsCRP)).
Materials and methods:We studied 744 individuals from the Hoorn Study (275 NGM, 176 IGM and 293 DM2,
mean age 68.6±7.1 years). Thrombin generation in platelet-poor plasma was measured using the Calibrated
Automated Thrombogram and three parameters were derived: lag time, peak height and endogenous
thrombin potential (ETP). Data were analyzed with multiple linear regression analyses.
Results: After adjustment for age, sex, prior CVD and smoking status, individuals with IGM or DM2 had a
longer lag time [ß=0.14 min (95% CI: 0.02; 0.26)], higher peak height [ß=7.29 nM (−1.33; 15.91)] and ETP
[ß=35.65nM*min (0.97; 70.34)] than those with NGM. These differences were attenuated to ß=0.06 min
(−0.07; 0.19), 3.82 nM (−5.46; 13.10) and 16.34 nM*min (−20.92; 53.59), respectively, when further
adjusted for waist circumference and hsCRP.
Conclusion: Individuals with IGM or DM2 had up to 4% higher thrombin generation compared with NGM,
which may be explained, to a great extent, by the greater levels of central adiposity and related low-grade
inﬂammation characterizing these individuals.
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vier OA license.Individualswith type2diabetes (DM2)havea2- to3-foldhigher risk
for cardiovascular disease (CVD) as compared with non-diabetic
individuals [1]. A substantial portion of diabetes-related macrovascular
complications is due to atherothrombotic events [2] which could, at
least in part, be explained by an association between impaired glucose
metabolism and thrombin generation. Indeed, thrombin plays a central
role in the coagulation cascade [3,4] and elevated levels of thrombin-
antithrombin (TAT) complexes and prothrombin 1.2 fragments (both in
vivo markers of thrombin generation) have been reported in patients
with DM2 [5–7].
Recently, several new methods have become available which
quantitatively measure thrombin generation, in vitro, after activation
of the coagulation cascade with tissue factor (TF), phospholipids and
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(CAT) is one such method [9,10]. Speciﬁcally, it generates a thrombin
generation curve that estimates the overall plasma coagulability
potential. The endogenous thrombin potential (ETP), or the area
under this curve, represents the total amount of active thrombin
that can be formed after activation of the coagulation cascade.
Measured as such, the ETP has been shown to be a good indicator of a
hypercoagulable state in, for example, individuals using oral contra-
ceptives, or who had prior venous thromboembolism [9,11–13].
Because the CAT method mimics the overall potential to clot
whenever a thrombogenic stimulus (e.g. TF release after plaque
rupture) appears, it is thought to provide amore reliable estimation of
coagulation under pathophysiological conditions than the single point
measurement of activation markers such as prothrombin 1.2
fragments or TAT complexes [14].
Only one small case-control study has investigated the association
between DM2 and thrombin generation according to this method [15].
However, no studies have been performed at the population level.
Establishing such an association is a necessary step to ascertain its
potential value as a tool to estimate atherothrombotic risk in individuals
with impaired glucose metabolism (IGM) and/or DM2. Furthermore,
from an etiological point of view, it is not clear whether any such
association is independent of other risk factors that typically character-
ize these individuals (e.g. hypertension and central adiposity) or,
alternatively, is explained by these risk factors and their associated
pathophysiological mechanisms. Central adiposity and related low-
grade inﬂammation are likely candidates in this regard [16]. Indeed,
individuals with IGM and DM2 have higher levels of high-sensitivity C-
reactive protein (hsCRP) which are, to a great extent, attributable to
their higher levels of (central) adiposity [17]. In addition, in vivo, hsCRP
has been associated with increased thrombin generation (assessed by
activation markers) [18].
In view of these considerations, we investigated, in a population-
based cohort, ﬁrst, whether individuals with IGM and/or DM2 had
greater levels of thrombin generation in plasma than thosewith NGM;
and second, whether any such differences were independent of other
cardiovascular risk factors and/or explained by (adiposity-related)
low-grade inﬂammation (hsCRP).
Materials and methods
Study population
For the present investigation, we used data from the 2000 Hoorn
Study follow-up examination and, to increase the number of
individuals with DM-2, data from The Hoorn Diabetes Screening
Study, both of which were population-based and have been described
in detail elsewhere [16,19,20]. Brieﬂy, the Hoorn Study is a cohort
study of glucose metabolism in the general population (n=2484),
which started in 1989 [20]. In 2000, a follow-up examination was
carried out among all surviving participants who had given their
permission to be recontacted. We invited all those who had diabetes,
as determined by an oral glucose tolerance test, or who were treated
for diabetes at the previous 1996 follow-up (n=176). Next, we
invited random samples of individuals with normal glucose metab-
olism (NGM) (n=705) and IGM (n=193). Of 1074 individuals thus
invited, 648 (60%) participated [19]. Additionally, we invited 217
individuals with DM-2 from the Hoorn Screening Study [21], of whom
188 (87%) participated. All participants underwent a glucose
tolerance test, except those with previously diagnosed diabetes
(n=67). Data on 14 individuals were missing because of logistical
problems. Glucose tolerance was deﬁned according to the 1999 WHO
criteria [22]. Altogether, the eligible cohort thus consisted of 822
individuals. For the present study, participants using cumarin de-
rivatives (n=25) and/or hormonal replacement therapy (n=3)
and/or having missing data on thrombin generation parameters(n=54) and/or in whom glucose metabolism status could not be
ascertained (n=14) were excluded. The present study therefore
consisted of 744 individuals: 275 with normal glucose metabolism
(NGM), 176 with IGM (including those with impaired fasting glucose
and/or impaired glucose tolerance) and 293 with DM2.
The Ethical Review Committee of the VUUniversityMedical Centre
approved the study protocol and all participants gave their written
informed consent.
Thrombin generation parameters
Venous blood samples were collected in 2000–2001 and 3.2%
citrated platelet-poor plasmas (PPP) were prepared by two-step
centrifugation: at 4000 ×g for 15 minutes followed by centrifugation
at 10000 ×g for 5 minutes. Plasmaswere stored at−80 °C until analysis
in 2008 and had not been thawed before. Thrombin generation in PPP
was measured using the CAT-method [10], which employs low-afﬁnity
ﬂuorogenic substrate for thrombin (Z-Gly-Gly-Arg-AMC) to continu-
ously monitor thrombin activity in clotting plasma. Thrombin genera-
tion was assessed according to manufacturer's instructions
(Thrombinoscope BV) in a 96-well plate ﬂuorometer (Ascent Reader,
Thermolabsystems OY, Helsinki, Finland) as previously described
[23].Brieﬂy, thrombin generation was determined in the presence of
1 pM TF and 4 uM phospholipids in the absence and presence of
0.55 nM recombinant soluble thrombomodulin (Paion GmbH, Aachen,
Germany). The 1 pM TF trigger was a commercial product (PPP Reagent
Low; Thrombinoscope BV, Maastricht, the Netherlands). Three param-
eters were derived from these analyses, i.e. lag time (min), peak height
(nM) and ETP (nM*min). A thrombomodulin ratio was calculated by
dividing the ETP andpeakheight in thepresence by those in the absence
of thrombomodulin. This ratio indicates the percentage inhibition of
thrombin generation by activation of the anti-coagulant protein C
pathway. At our lab, the intra-assay coefﬁcients of variation (CVs) are
b5% [13] and the inter-assay CVs , obtained in 2 lots of normal-pool
plasma in 25 independent runs during the present study, were b11% for
all thrombin generation parameters (calculated using the EP Evaluator
8.0.0.90 software).
Other measurements
Health status, medical history, medication use and smoking habits
were assessed by questionnaires [20]. We measured waist circumfer-
ence, bodymass index (BMI), systolic (SBP) and diastolic blood pressure
(DBP), levels plasma glucose (fasting and post-load), HbA1c, total, high-
(HDL) and low-density lipoprotein (LDL) cholesterol, triglycerides,
urinary albumin-to-creatinine ratio and hsCRP as described in detail
elsewhere [20,24,25]. Hypertension was deﬁned as SBP ≥140 mmHg
and/or DBP≥90 mmHg and/or the use of anti-hypertensive drugs [26].
Participants were classiﬁed as havingmicroalbuminuria if the albumin-
to-creatinine ratio was ≥2.0 mg/mmol [24]. Prior CVD was deﬁned as
described previously [16].
Statistical analyses
Variables with a skewed distribution (i.e. triglycerides and hsCRP)
were log-transformed prior to further analyses. Comparisons of the
clinical characteristics according to individuals’ glucose metabolism
status were investigated by means of analyses of variance (ANOVA)
for continuous variables and chi-squared tests for frequency data.
We used multiple linear regression analyses to investigate the
differences in thrombin generation parameters between individuals
with IGM or DM2 vs. NGM (reference group). These analyses were
ﬁrst adjusted for age, sex, prior CVD and smoking status (model 1),
and additionally for measures of blood pressure, dyslipidemia,
(micro)albuminuria, glycemic control, (central) adiposity and low-
grade inﬂammation (models 2 to 7). In addition, we investigated
Table 1
Clinical characteristics according to glucose metabolism status.
NGM (n=275) IGM (n=176) DM2 (n=293) p for linear trend
Age (years) 68.5±6.0 70.3±6.5 67.6±8.0 0.099
Sex (% male) 47.3 50.6 50.9 0.397
Fasting glucose (mmol/l) 5.42±0.37 6.08±0.48 7.71±1.80 b0.001
Glycated haemoglobin (%) 5.68±0.41 5.88±0.39 6.61±0.92 b0.001
Body mass index (kg/m2) 26.2±3.3 27.8±4.1 29.1±4.6 b0.001
Waist circumference (mm) 90.7±11.0 97.3±10.8 101.1±12.0 b0.001
Total cholesterol (mmol/l) 5.79±1.03 5.79±1.02 5.53±1.06 0.003
LDL-cholesterol (mmol/l) 3.71±0.91 3.68±0.92 3.46±0.92 0.001
HDL-cholesterol (mmol/l) 1.51±0.41 1.44±0.40 1.24±0.34 b0.001
Total-to-HDL cholesterol ratio 4.05±1.09 4.32±1.39 4.71±1.32 b0.001
Triglycerides (mmol/l) 1.20 [0.90-1.50] 1.30 [1.00-1.70] 1.60 [1.20-2.20] b0.001
Lipid lowering drugs (%) 12.4 15.9 19.9 0.016
Systolic blood pressure (mmHg) 137±20 143±18 146±21 b0.001
Diastolic blood pressure (mmHg) 81±11 83±10 85±10 b0.001
Mean arterial pressure (mmHg) 95±11 100±10 102±11 b0.001
Use of antihypertensives (%) 23.4 37.5 50.3 b0.001
Microalbuminuria (%) 9.8 15.9 18.8 0.003
Smoking (%) 13.9 17.6 12.1 0.525
Prior CVD (%) 45.1 50.0 53.2 0.053
Use of Platelet aggregation inhibitors (%) 13.2 16.5 19.8 0.038
High-sensitivity C-reactive protein (mg/l) 1.52 [0.80; 3.14] 2.19 [1.29; 4.61] 3.14 [1.42; 7.00] b0.001
Results are expressed as percentages (%), mean±SD, or median [inter-quartile range].
NGM: normal glucose metabolism; IGM: impaired glucose metabolism; DM2: type 2 diabetes mellitus; LDL: low density lipoprotein; HDL: high density lipoprotein; CVD:
cardiovascular disease.
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driven by adding adjustments for bothwaist circumference and hsCRP
(model 8). In all these analyses individuals with IGM and DM2 were
combined into one group, since the parameters of thrombin
generation examined herein did not substantially differ between
these two groups. In all analyses described above, dependent
variables were the thrombin generation parameters obtained in
both the absence and presence of thrombomodulin.
Statistical signiﬁcance was set at a p-value of b0.05. All analyses
were performed with the use of the Statistical Package for Social
Sciences (SPSS) for Windows, version 15.0 (SPSS Inc., Chicago, IL,
USA).
Results
Participants who were excluded from the analyses (n=78) were
younger, more often obese andmore often had diabetes than the ones
included (data not shown). The clinical characteristics of the
participants included (n=744) are shown in Table 1 according to
their glucose metabolism status. A deteriorating glucose metabolism
status was associated with a larger waist circumference and higher
levels of dyslipidemia, blood pressure, microalbuminuria, hsCRP andTable 2
Thrombin generation parameters according to glucose metabolism status.
NGM
(n=275)
IGM
(n=
Analyses without thrombomodulin
Lag time (min) 3.98±0.83 4.1
Peak Height (nM) 182±57 19
ETP (nM*min) 1166±222 121
Analyses with thrombomodulin
Lag time (min) 3.91±0.68 4.0
Peak height (nM) 159±60 16
ETP (nM*min) 776±253 81
Thrombomodulin ratio
TM ratio Peak height n=737 0.86±0.11 0.8
TM ratio ETP n=737 0.65±0.14 0.6
Results are expressed as mean±SD.
NGM: normal glucose metabolism; IGM: impaired glucose metabolism; DM2: type 2 diabetprior CVD. In addition, participants with IGM and DM2 more often
used lipid-lowering drugs and platelet aggregation inhibitors those
with NGM.
Levels of lag time, peak height and ETP assessed in the absence of
thrombomodulin were comparable in individuals with IGM and DM2
and greater in these individuals than in those with NGM (Table 2,
Fig. 1). Activating the anticoagulant protein C pathway by adding
thrombomodulin did not affect the absolute values of lag time but led
to lower absolute values of peak height and ETP, which were reduced
by approximately 14 and 35%, respectively, in all groups (Table 2).
Despite the relatively higher values in individuals with IGM and DM2
under these conditions, peak height and ETP did not differ
signiﬁcantly from those of individuals with NGM, however lag time
remained signiﬁcantly prolonged. The thrombomodulin ratio of peak
height and ETP did not materially differ between the 3 groups
(Table 2).
Associations between glucose metabolism status and thrombin
generation parameters
After adjustment for age, sex, prior CVD and smoking status,
individuals with IGM or DM2 had a signiﬁcantly prolonged lag time, a176)
DM2
(n=293)
p-value
(IGM+DM2 vs. NGM)
0±0.80 4.14±0.77 0.021
1±58 189±59 0.067
8±237 1192±238 0.034
6±0.71 4.06±0.76 0.005
6±60 167±65 0.104
0±256 807±261 0.106
6±0.10 0.86±0.14 0.867
5±0.14 0.66±0.15 0.559
es mellitus; ETP endogenous thrombin potential; TM: thrombomodulin.
Fig. 1. Thrombin generation curves according to glucose metabolism status i.e. Normal
glucose metabolism (NGM), impaired glucose metabolism (IGM) or type 2 diabetes
mellitus (DM2).
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model 1). In relative terms, these differences were small and
equivalent to approximately a 4% longer lag time, a 4% higher peak
height and a 3% higher ETP in individuals with IGM or DM as
compared with those with NGM. In addition, the differences in peak
height and ETP were attenuated to a great extent when further
adjusted for waist circumference (model 6) and hsCRP (model 7),
whereas adjustments for the other risk factors considered did not
materially affect these results (models 2 to 5). When differences
between groups were adjusted for both waist circumference and
hsCRP (model 8), results were similar to those obtained in model 7,
thus suggesting that any ‘mediation’ by low-grade inﬂammation was
adiposity-driven. In contrast to the above, the differences in lag time
were mainly attenuated by dyslipidaemia.Table 3
Thrombin generation parameters according to glucose metabolism status.
Lag time (mi
Model Adjustments β
Without thrombomodulin
0 Crude 0.14*
1 Age, sex, prior CVD, smoking 0.14*
2 Model 1+SBP 0.13*
3 Model 1+total cholesterol/ HDL ratio and ln-triglycerides 0.04
4 Model 1+microalbuminuria 0.12*
5 Model 1+HbA1c 0.07
6 Model 1+waist circumference 0.09
7 Model 1+ln-hsCRP 0.09
8 Model 1+waist circumference and ln-hsCRP 0.06
With thrombomodulin
0 Crude 0.15†
1 Age, sex, prior CVD, smoking 0.15†
2 Model 1+SBP 0.13*
3 Model 1+total cholesterol/ HDL ratio and ln-triglycerides 0.07
4 Model 1+microalbuminuria 0.13*
5 Model 1+HbA1c 0.08
6 Model 1+waist circumference 0.09
7 Model 1+ln-hsCRP 0.09
8 Model 1+waist circumference and ln-hsCRP 0.06
Regression coefﬁcient (β) with respective 95%CI indicates the difference in thrombin generSimilar ﬁndings were obtained when analyses compared the
parameters of thrombin generation obtained in the presence of
recombinant thrombomodulin (second part Table 3).
Additional analyses
Additional adjustment for use of platelet aggregation inhibitors, or
lipid- , blood pressure- or glucose-lowering drugs did not materially
affect any of the reported associations (data not shown).
We also investigated whether the association between glucose
metabolism status and thrombin generation parameters differed
between men and women or between different age categories, by
adding interaction terms to our models. However, no such interactions
were found (p-values for interaction all N0.10).
Discussion
The main ﬁndings of this study were two-fold: ﬁrst, individuals
with IGM and DM2 had comparable levels and both had higher levels
of thrombin generation than those with NGM, but the magnitude of
these differences was relatively small (up to 4%). Second, central
adiposity and related low-grade inﬂammation explained to a great
extent the association between glucose tolerance status and thrombin
generation, i.e., peak height and ETP.
The modest elevations in thrombin generation parameters suggest
that thrombin generation in PPP only slightly contributes to the
hypercoagulable state in IGM and DM2. This observation is in line
with a recently published case-control study in DM2 patients that also
reported minimal differences between DM2 patients compared with
healthy controls [15]. Alterations in primary hemostasis and/or the
ﬁbrinolytic system may thus be more important in establishing the
hypercoagulable state in IGM and/or DM2 than those reﬂected by the
thrombin generation assay on which we focused herein. For example,
DM2 is associated with increased platelet activation and aggregation
and von Willebrand factor levels [27,28] and plasminogen activator
inhibitor (PAI)-1 levels are elevated in DM2, probably due to an
increased hepatic synthesis [29]. PAI-1 inhibits ﬁbrinolysis, which is
associatedwithmore resistant clot formation and possibly plays a role
in vascular complications such as atherothrombosis.
The thrombin generation parameters were elevated to a similar
extent in individuals with IGM and DM2, which is in line with an) Peak height (nM) ETP (nM*min)
95%CI β 95%CI β 95%CI
0.02; 0.26 7.98 −0.63; 16.58 36.75* 2.17; 71.34
0.02; 0.26 7.29 −1.33; 15.91 35.65* 0.97; 70.34
0.01; 0.25 6.42 −2.34; 15.18 32.80 −2.46; 68.07
−0.08; 0.16 8.16 −0.79; 17.11 34.29 −1.88; 70.47
0.01; 0.24 7.10 −1.57; 15.76 34.31 −0.56; 69.17
−0.06; 0.20 6.95 −2.49; 16.39 41.54* 3.56; 79.52
−0.04; 0.22 5.48 −3.76; 14.71 23.85 −13.26; 60.97
−0.03; 0.21 4.57 −4.22; 13.36 22.90 −12.40; 58.19
−0.07; 0.19 3.82 −5.46; 13.10 16.34 −20.92; 53.59
0.04; 0.26 7.54 −1.66; 16.74 31.21 −6.90; 69.33
0.04; 0.25 6.80 −2.41; 16.02 27.89 −10.28; 66.03
0.03; 0.24 6.18 −3.19; 15.55 26.39 −12.42; 65.21
−0.04; 0.18 7.95 −1.62; 17.53 34.87 −4.86; 74.60
0.02; 0.23 6.78 −2.48; 16.04 27.42 −10.95; 65.79
−0.03; 0.20 6.60 −3.49; 16.69 32.42 −9.37; 74.21
−0.03; 0.20 5.15 −4.72; 15.02 22.07 −18.83; 62.97
−0.02; 0.20 4.26 −5.15; 13.66 17.15 −21.80; 56.10
−0.06; 0.17 3.60 −6.34; 13.53 15.43 −25.71; 56.56
ation parameter (in respective units) in IGM/DM2 vs. NGM. *pb0.05, †pb0.01.
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hypothesis’ suggesting that hemostatic disturbances may be present
even before fully developed diabetes [31].
The prolonged lag time in IGM and DM2 may be explained by
elevated tissue factor pathway inhibitor (TFPI) levels, which is one of
the main determinants of lag time at the low TF concentrations used
in our study [23]. In addition, previous studies have shown a positive
association between glucose metabolism status and TFPI [30,32]. In
the present study, the association between glucose metabolism status
and lag time was partially attenuated by dyslipidemia, which is in line
with previous studies that have shown a positive association between
dyslipidemia and TFPI [33,34].
The associations between glucose metabolism status and peak
height and ETP were to a great extent attenuated by waist circumfer-
ence, suggesting that central adipositymay be a common antecedent of
both IGM/DM2 and increased thrombin generation.We have previously
shown in this cohort that individuals with a central pattern of fat
distribution indeed had higher levels of thrombin generation in plasma,
whichwere to a great extent explained by adiposity-related increases in
hsCRP [16]. Furthermore, a recentmeta-analysis supports theseﬁndings
by suggesting that the elevated hsCRP levels in DM2 are probably due to
central adiposity [17]. One proposed mechanism by which hsCRP, or
low-grade inﬂammation in general, may lead to increased thrombin
generation may be by inducing endothelial dysfunction which in turn
leads to increased TF expression by monocytes [35], a phenomenon
which is only observed in the presence of and through direct interaction
with other leukocytes [36]. Taken together, our ﬁndings thus suggest
that adiposity-related low-grade inﬂammation and not hyperglycemia
per se might be one of the main driving factors behind the association
between glucosemetabolism status and thrombin generation in PPP. In
addition, previous studies have not found an association between
glycemic control and prothrombin 1.2 fragments and/or TAT-complexes
[37,38]. However, these studies did ﬁnd an association between
glycemic control and thrombin generation in platelet-rich plasma,
suggesting that associations between glycemic control and thrombin
generation might mainly be a platelet-dependent phenomenon [39].
There are some limitations to our study that need to bementioned.
First, due to its cross-sectional design, any inferences about causality
should be made with caution. Second, as we studied a relatively
elderly population, we cannot fully exclude the possibility that
selective mortality in the diabetes group (i.e. many ‘healthy’ survivors
included in this study) may have explained their comparable (instead
of higher) levels of thrombin generation parameters as compared
with the individuals with IGM. Third, we studied a Caucasian, elderly
population and it remains to be established whether these results can
be generalized to other ethnicities and/or to younger individuals.
Fourth, measures of thrombin generation were performed in plasma
samples that were stored for 7 to 8 years. Although in our lab we have
been able to rule out effects of approximately one year of storage time
on ex vivo thrombin generation, long term effects, if any, are largely
unknown. If long term storage introduced a systematic error in
measures of thrombin generation, we can rule out its inﬂuence on the
differences found between the groups examined in the present study,
since storage timewas similar for all plasma aliquots. If random errors
were introduced, or even if storage time reduced the variation of the
measures as captured by our assay, then the differences between
groups reported herein were most likely underestimated. Finally, it
should be noted that, in the present cohort, it is unknown which
individuals carried the factor V Leiden mutation. In general, these
individuals will have a higher thrombin generation due to activated
protein C resistance and an association between DM2 and the factor V
Leiden mutation has been previously reported [40]. However, several
other studies, including a Dutch one, did not ﬁnd any association
between DM2 and factor V Leidenmutation [41–43]. So far, no studies
have investigated the association between DM2 and acquired
activated protein C resistance. We have shown herein that activatingthe protein C pathway by adding thrombomodulin did not materially
change the strength of the associations between glucose metabolism
status and peak height or ETP, which indicates that there were no
abnormalities in protein C activation in individuals with IGM or DM2.
In conclusion, we have shown that IGM and DM2 are associated
with higher thrombin generation in PPP, which can be explained, to a
large extent, by their greater levels of central adiposity and related
low-grade inﬂammation. It remains to be established whether the
assessment of thrombin generation in PPP constitutes a useful method
for the characterization of hypercoagulability, relevant to arterial and
venous thrombosis, in these individuals, since the magnitude of the
differences was relatively small.Conﬂict of interest statement
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